Single-Atom Nanozymes for High-Efficiency Cancer Immunotherapy by Targeting Tumor Microenvironment.

Authors

Lulu Zhang, Mingming Yin, Bing-Hao Wang, Rong Xu, Boyao Tan, Yi Chen

Published in

Advanced healthcare materials. Pages e71567. Aug 12, 2026. Epub Aug 12, 2026.

Abstract

Tumor immunotherapy has emerged as a transformative strategy for cancer treatment. However, its clinical efficacy remains limited by the immunosuppressive tumor microenvironment (TME), which restricts immune cells infiltration, suppresses effector cells activity, and promotes immune escape. Recent advances in catalytic nanomedicine have highlighted single-atom nanozymes (SAzymes) as a promising platform for overcoming these barriers. Owing to their atomic precision and tunable electronic structure, SAzymes exhibit highly efficient enzyme-like catalytic activities and enable precise regulation of the TME. Through catalytic therapy, SAzymes can alleviate hypoxia, regulate lactate accumulation, disrupt redox homeostasis, and reprogram immunosuppressive immune cells populations. Importantly, SAzyme-mediated catalytic therapy can induce immunogenic cell death (ICD), thereby enhancing antitumor immune responses. In addition, the well-defined atomic architecture of SAzymes provides a unique opportunity to establish quantitative structure-activity relationships (QSAR), enabling rational optimization of catalytic performance through modulation of their composition and coordination environment. This review systematically summarizes the mechanisms by which SAzymes remodel the TME and enhance cancer immunotherapy, discussing recent advances in atomic level design principles and multimodal synergistic therapy. Finally, current challenges and future perspectives, including machine learning-guided SAzymes design, biosafety and clinical translation, are discussed to guide the next generation of SAzyme-based catalytic immunotherapies.

PMID:
42590854
Bibliographic data and abstract were imported from PubMed on 13 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.